Abstract
Eosinophilic diseases comprise a heterogeneous spectrum of conditions characterized by increased eosinophil counts and tissue infiltration, ranging from organ-specific allergic disorders to systemic inflammatory, autoimmune, and hematologic diseases. Although traditionally classified according to the primary organ involved, increasing evidence indicates that eosinophilia often reflects a systemic immune dysregulation with shared pathogenic mechanisms and overlapping clinical phenotypes. This complexity challenges purely organ-based diagnostic and therapeutic approaches and underscores the need for biomarker-driven strategies. Eosinophils act as multifunctional effector cells bridging innate and adaptive immunity and contribute to tissue damage, vascular dysfunction, and thrombotic complications through the release of cytotoxic granule proteins, cytokines, and lipid mediators. In this context, circulating inflammatory and coagulation-related biomarkers provide a non-invasive window into disease activity, pathogenic pathways, and risk stratification. Peripheral blood eosinophil count remains a central marker, while markers of coagulation activation, mast cell–derived mediators, complement components, and type 2 inflammatory biomarkers capture complementary dimensions of eosinophilic inflammation. In airway diseases such as eosinophilic asthma and chronic rhinosinusitis with nasal polyps, integration of cytokine biology with circulating and airway biomarkers has enabled biomarker-guided selection of biologic therapies targeting interleukin (IL)-5, IL-4/IL-13, and upstream epithelial alarmins. Conversely, in systemic eosinophilic syndromes, immune-mediated diseases, and eosinophilic gastrointestinal disorders, validated serum biomarkers capable of guiding diagnosis and monitoring remain limited, highlighting important unmet clinical needs. Among currently available markers, blood eosinophil count has the clearest established clinical utility in severe eosinophilic asthma and CRSwNP, whereas tryptase, ANCA, C-reactive protein, IgG4, D-dimer, fibrinogen, ECP, and EDN provide context-dependent adjunctive or investigational information in systemic disease and EGID. This review provides an integrated overview of inflammatory serum biomarkers across eosinophilic diseases, emphasizing their role in disease phenotyping, risk assessment, and precision medicine. By bridging perspectives from internal medicine, immunology, pulmonology, rheumatology, and gastroenterology, we propose a unified, biomarker-informed framework to support individualized management across the eosinophilic disease spectrum. No single serum biomarker reliably captures tissue activity across all eosinophilic disorders; longitudinal interpretation together with clinical phenotype, treatment exposure, and organ-specific assessment is therefore essential.
Keywords: eosinophilic diseases, eosinophilia, serum biomarkers, precision medicine, type 2 inflammation
Introduction
Eosinophilia represents a complex immunological trait that spans a broad spectrum of diseases, ranging from organ-specific allergic conditions to systemic inflammatory, autoimmune, and hematologic disorders.1 Traditionally, eosinophilic diseases have been classified according to the primary organ involved, such as the airways, gastrointestinal tract, skin, or cardiovascular system. However, accumulating evidence indicates that eosinophilia frequently reflects a systemic immune dysregulation rather than an isolated tissue-limited process, with shared pathogenic pathways and overlapping clinical phenotypes across different disease entities.2
From a mechanistic perspective, eosinophils act as multifunctional effector cells at the interface between innate and adaptive immunity.3 Beyond their established role in host defense and type 2 inflammation, eosinophils actively contribute to tissue injury, vascular inflammation, thrombosis, and immune modulation through the release of cytotoxic granule proteins, lipid mediators, cytokines, and growth factors.4 As a consequence, sustained eosinophilic activation can drive multisystem involvement, with clinically relevant manifestations affecting the heart, kidneys, liver, gastrointestinal tract, and vascular compartment. This systemic dimension of eosinophilic inflammation challenges purely organ-based diagnostic and therapeutic approaches.
In this context, serum biomarkers have emerged as critical tools to capture the biological activity of eosinophilic diseases beyond local tissue findings.5 Peripheral blood eosinophil count, markers of coagulation activation, mast cell–derived mediators, complement components, and type 2 inflammatory biomarkers provide complementary information on disease mechanisms, activity, and risk of complications. Importantly, no single biomarker is sufficient to fully characterize eosinophilic inflammation.6 Rather, the integration of multiple circulating markers is increasingly recognized as necessary to reflect the heterogeneity and dynamic nature of eosinophilic inflammation across different clinical contexts.
The growing availability of targeted therapies, particularly biologic agents directed against key cytokine pathways such as interleukin (IL)-5, IL-4/IL-13, and upstream epithelial alarmins, has further amplified the need for biomarker-driven patient stratification.7 In airway diseases, biomarker-informed approaches have already reshaped clinical decision-making, enabling more precise selection of therapies and improved outcomes. Conversely, in systemic eosinophilic syndromes, autoimmune diseases, and eosinophilic gastrointestinal disorders, validated biomarkers capable of guiding treatment selection and monitoring remain limited, highlighting important unmet clinical needs. The role of circulating biomarkers across the spectrum of eosinophilic diseases is summarized in Figure 1.
Figure 1.

Conceptual framework of serum biomarkers across eosinophilic diseases. The figure illustrates how circulating serum biomarkers reflect different layers of eosinophilic disease biology across a spectrum of systemic and organ-specific conditions. In systemic hypereosinophilia, serum biomarkers primarily capture inflammatory burden, organ involvement, and thrombotic risk, with limited ability to guide targeted therapy. In immune-mediated eosinophilic diseases, such as eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndromes, biomarkers provide partial stratification in the context of marked biological heterogeneity. In eosinophilic asthma and chronic rhinosinusitis with nasal polyps, integration of type 2 cytokine pathways with circulating and airway biomarkers enables biomarker-guided biologic therapy and represents a successful model of precision medicine. In contrast, eosinophilic gastrointestinal diseases highlight the limitations of serum biomarkers, which poorly reflect tissue-restricted inflammation and require integrated clinical, endoscopic, and histological assessment. The progressive transition from systemic inflammation to biomarker-guided precision medicine highlights the heterogeneous level of biomarker implementation across eosinophilic diseases.
Against this background, the present review aims to provide an integrated overview of inflammatory serum biomarkers across the spectrum of eosinophilic diseases, with a specific focus on their role in disease phenotyping, risk stratification, and precision medicine approaches. By bridging insights from internal medicine, immunology, pulmonology, rheumatology, and gastroenterology, this work seeks to move beyond organ-centered frameworks and to propose a unifying, biomarker-driven perspective on eosinophilic diseases. Such an approach is essential to translate mechanistic advances into clinically meaningful strategies for individualized patient management.
Current knowledge is unevenly translated into clinical practice. In eosinophilic asthma and CRSwNP, blood eosinophils and complementary airway biomarkers are already incorporated into endotyping and biologic-treatment pathways. Conversely, in HES, EGPA, immune-mediated eosinophilic disorders, and EGID, many candidate biomarkers have biological plausibility but limited analytical standardization, external validation, disease specificity, or actionable thresholds. A cross-disease appraisal is therefore needed to clarify not only what each biomarker measures, but also when it changes clinical management and when it should remain an adjunct to tissue- or organ-based evaluation.
Accordingly, this review aims to: (i) explain the inflammatory mechanisms that generate measurable serum signals; (ii) critically appraise the diagnostic, phenotypic, prognostic, predictive, and monitoring value of serum biomarkers across eosinophilic diseases; (iii) distinguish biomarkers with established clinical utility from adjunctive or exploratory candidates; and (iv) propose a practical framework for integrating biomarkers with organ-specific assessment.
This narrative review was based on a non-systematic literature search conducted through PubMed, Scopus, and Web of Science, focusing on studies addressing serum biomarkers, eosinophilic inflammation, and precision medicine approaches across eosinophilic diseases. Priority was given to recent evidence, landmark studies, consensus documents, and clinically relevant translational research.
Eosinophils as Central Effectors of Inflammation
Eosinophils arise from myeloid progenitors under the influence of IL-5, with additional support from IL-3 and granulocyte-macrophage colony-stimulating factor. IL-5 promotes differentiation, bone-marrow release, survival, and priming, whereas eotaxins acting through CCR3 and adhesion molecules regulate trafficking into inflamed tissues. The blood eosinophil count therefore reflects the balance between production, tissue recruitment, cell death, and treatment exposure rather than a direct measurement of tissue eosinophilia.3
Eosinophil activation occurs within a broader inflammatory network. Epithelial alarmins, including TSLP, IL-25, and IL-33, activate dendritic cells, type 2 innate lymphoid cells, and Th2 lymphocytes, leading to IL-4, IL-5, and IL-13 production. These pathways amplify recruitment and survival and help explain why eosinophilic inflammation may persist even when a single circulating mediator changes only modestly.7
Complement-derived anaphylatoxins and reciprocal interactions with mast cells further amplify eosinophil migration, oxidative burst, and degranulation. Histamine, proteases, lipid mediators, cytokines, C3a, and C5a create an interconnected inflammatory circuit rather than independent biomarker axes.3
Activated eosinophils exert their effects through classical and piecemeal degranulation, cytolysis, and extracellular trap formation. Released granule proteins, reactive oxygen species, leukotrienes, cytokines, growth factors, and tissue factor can injure epithelium and endothelium, activate platelets and coagulation, and promote remodeling and fibrosis. An overview of the major mechanisms involved in eosinophilic inflammation, from triggering signals and immune amplification to eosinophil recruitment, activation, tissue injury, and clinically measurable circulating biomarkers, is shown in Figure 2.
Figure 2.

Overview of the mechanisms involved in eosinophilic inflammation. The figure summarizes the major pathways contributing to eosinophilic inflammation, from triggering factors and epithelial barrier dysfunction to immune amplification, eosinophilopoiesis, tissue recruitment, eosinophil activation, and effector responses. Epithelial alarmins, including TSLP, IL-25, and IL-33, activate dendritic cells, type 2 innate lymphoid cells, Th2 lymphocytes, mast cells, and complement pathways, leading to the release of key mediators such as IL-4, IL-5, IL-13, C3a, and C5a. These signals promote eosinophil differentiation, survival, and trafficking through eotaxins, CCR3, and adhesion molecules. Activated eosinophils contribute to tissue injury through degranulation, extracellular trap formation, and the release of granule proteins, cytokines, lipid mediators, and reactive oxygen species. The downstream consequences include epithelial damage, mucus hypersecretion, edema, tissue remodeling, fibrosis, vascular injury, and thrombosis. The figure also highlights clinically relevant circulating biomarkers, including blood eosinophils, ECP, EDN, tryptase, ANCA, IgG4, CRP, D-dimer, and fibrinogen, across the major eosinophilic disease domains.
Systemic Eosinophilia as a Multisystem Disease: Biomarkers of Organ Infiltration and Prothrombotic Risk
From an internal medicine perspective, the clinical burden of hypereosinophilia is primarily driven by two interrelated pathogenic mechanisms: direct eosinophilic infiltration of target organs and systemic activation of coagulation, resulting in a prothrombotic phenotype.8,9 These mechanisms frequently coexist but may predominate differently across patients and disease entities, including hypereosinophilic syndromes (HES), eosinophilic granulomatosis with polyangiitis (EGPA), drug-induced hypersensitivity reactions, and selected hematologic neoplasms.10
Circulating inflammatory and coagulation-related biomarkers provide a non-invasive window into these pathogenic processes and represent essential tools for disease phenotyping, risk stratification, and monitoring therapeutic response.11,12 In this context, peripheral blood eosinophil count, fibrinogen, D-dimer, and serum tryptase capture complementary aspects of eosinophil-driven tissue injury, vascular inflammation, and thrombotic risk, with particular relevance for cardiac, hepatic, and renal involvement.
Organ Infiltration as a Major Complication of Hypereosinophilia
Cardiac Involvement
Cardiac involvement represents the most severe and prognostically relevant manifestation of eosinophilic diseases. While pericardial involvement may occur, eosinophilic myocarditis and progressive endomyocardial damage are more characteristic and clinically impactful.13 Eosinophilic infiltration of the myocardium leads to cardiomyocyte necrosis mediated by cytotoxic granule proteins, followed by thrombotic deposition and fibrotic remodeling. If untreated, this process may evolve toward restrictive cardiomyopathy with irreversible functional impairment.
Peripheral blood eosinophil count remains a central biomarker and correlates with the risk of myocardial involvement, although cardiac damage may occur even in the absence of extreme eosinophilia.14 Persistent eosinophil elevation should therefore prompt cardiovascular evaluation, particularly in patients presenting with dyspnea, chest pain, arrhythmias, or signs of heart failure.
Fibrinogen, as an acute-phase reactant, may be elevated during active myocardial inflammation and reflects systemic cytokine-driven inflammatory responses. Although nonspecific, increased fibrinogen supports the presence of an inflammatory phenotype and may contribute to microvascular dysfunction within the myocardium. Serum tryptase may provide additional diagnostic information, particularly in identifying clonal or mast cell–associated disorders in which cardiac involvement occurs as part of a broader myeloid disease.15 Elevated baseline tryptase levels warrant further hematologic evaluation to investigate systemic mastocytosis.
Hepatic Involvement
The liver is a frequent but often under-recognized target of eosinophilic infiltration. Hepatic involvement may manifest as asymptomatic elevation of transaminases, cholestatic patterns, hepatomegaly, or, more rarely, eosinophilic hepatitis. Liver involvement occurs especially in drug reactions with eosinophilia and systemic symptoms (DRESS), a severe delayed drug hypersensitivity reaction typically characterized by eosinophilia, organ involvement, fever, and viral reactivation (in particular HHV-6).16
In patients with hypereosinophilia and abnormal liver enzymes, careful exclusion of alternative causes, including drug-induced liver injury, parasitic infections, and autoimmune liver disease, is essential. In selected cases, liver biopsy may be required to differentiate active inflammatory infiltration from fibrotic or vascular complications, which have important therapeutic implications.
Renal Involvement
Renal manifestations of eosinophilic diseases include eosinophilic interstitial nephritis, glomerulonephritis (particularly in EGPA), and vascular involvement.10 Clinically, renal infiltration may present with acute kidney injury, proteinuria, hematuria, or hypertension. While peripheral eosinophil count provides an indirect marker of disease activity, systemic inflammatory biomarkers such as fibrinogen reflect the overall inflammatory burden.
In selected patients, elevated D-dimer levels may suggest the presence of renal microvascular thrombosis, highlighting the overlap between infiltrative and thrombotic mechanisms.9 Early recognition of renal involvement is crucial, as timely treatment may prevent irreversible renal damage.
The Prothrombotic Phenotype in Eosinophilic Diseases
Beyond tissue infiltration, hypereosinophilia is increasingly recognized as a systemic prothrombotic condition.9,17 Thrombotic complications include deep vein thrombosis, pulmonary embolism, intracardiac thrombi, and microvascular thrombosis affecting multiple organs. Importantly, these events may occur independently of traditional cardiovascular risk factors.
Eosinophils contribute directly to thrombosis through multiple mechanisms, including expression of tissue factor, release of procoagulant granule proteins, platelet activation, and induction of endothelial injury. These processes establish a direct link between inflammation and coagulation activation, explaining the high thrombotic burden observed in eosinophilic disorders.
Circulating Biomarkers and Clinical Implications
Growing evidence indicates that elevated eosinophil counts are independently associated with increased cardiovascular risk, extending beyond their traditional role in allergic and parasitic diseases.8 Hypereosinophilia contributes to cardiovascular damage through direct myocardial infiltration, endothelial dysfunction, and promotion of a prothrombotic milieu.
Eosinophils exert cardiotoxic effects through the release of cationic granule proteins, such as major basic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin, which induce cardiomyocyte injury, oxidative stress, and endothelial activation. In eosinophilic myocarditis, this eosinophil-mediated necrosis represents an early and potentially reversible disease stage, which may progress to mural thrombosis and restrictive cardiomyopathy if left untreated.
Beyond tissue infiltration, eosinophils actively promote systemic thrombosis by expressing tissue factor, activating platelets, and interacting with neutrophil extracellular traps. This mechanistic link explains the high prevalence of intracardiac thrombi, embolic events, and microvascular ischemia observed in HES, EGPA, and selected drug-induced eosinophilic reactions.
From a clinical perspective, persistent eosinophilia, particularly values exceeding 1500 cells/µL, should be considered a non-traditional cardiovascular risk marker.10 Patients with sustained eosinophil elevation warrant systematic cardiovascular assessment, including echocardiography and cardiac biomarkers, even in the absence of overt cardiac symptoms.
Tryptase
Serum tryptase identifies a distinct but overlapping pathogenic axis linking mast cell activation, clonal myeloid disorders, and cardiovascular risk. Persistent tryptase elevation is most commonly associated with clonal mast cell disease, myeloid neoplasms with eosinophilia, or combined mast cell–eosinophilic disorders, conditions characterized by a particularly high burden of cardiovascular complications.
Mast cells play a critical role in cardiovascular pathology through the release of tryptase, histamine, cytokines, and proteases that promote vascular inflammation, endothelial dysfunction, and coagulation activation. Clinically, elevated tryptase levels have been associated with myocardial fibrosis, coronary microvascular dysfunction, and thrombotic events.
D-Dimer
D-dimer is a key biomarker of fibrin formation and degradation and is frequently elevated in eosinophilic diseases with active thrombosis or endothelial activation.9,18 Elevated D-dimer levels may precede clinically overt thromboembolic events, particularly in patients with marked hypereosinophilia.
Fibrinogen
Fibrinogen elevation reflects both inflammatory activity and increased thrombotic potential. In eosinophilic diseases, elevated fibrinogen may act synergistically with eosinophil-mediated endothelial injury, promoting clot formation and vascular dysfunction.19 Serial monitoring of fibrinogen levels may help identify patients with sustained inflammatory and prothrombotic activity, even in the absence of clinically evident thrombosis.
EGPA and Hypereosinophilic Syndromes: Biomarkers Across Overlapping Disease Spectra
EGPA is classically described as a small-vessel, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, although only approximately 30–47% of patients with EGPA are ANCA-positive, mostly exhibiting anti-myeloperoxidase ANCA positivity.
ANCA-positive and ANCA-negative presentations of EGPA have recently been shown to be associated with distinct genetic polymorphisms suggesting distinct underlying pathogenic mechanisms: MPO-ANCA-positive EGPA, dominated by vasculitic lesions, and ANCA-negative EGPA, characterized by eosinophilic manifestations.20,21
In particular, ANCA-positive EGPA patients are more prone to developing a vasculitic phenotype characterized by necrotizing vasculitis and glomerulonephritis, whereas ANCA-negative EGPA patients appear more likely to develop the consequences of eosinophilic organ infiltration.22 However, ANCA status alone is insufficiently sensitive or specific to predict clinical presentation, and cannot guide treatment decisions.
Typically, EGPA begins with a prodromal phase, including asthma and/or chronic rhinosinusitis (with or without polyposis) and with some degree of blood eosinophilia. Marked hypereosinophilia is associated with tissue infiltration, particularly in the lungs, and may precede the development of necrotizing vasculitis or extravascular eosinophil-rich granulomas if left untreated. The interval between initial presenting symptoms and vasculitis can vary among patients and may be influenced by treatments. But, EGPA is not only a lung disease, as demonstrated by the involvement of multiple organ systems. From a pathobiological point of view, EGPA is characterized by eosinophilic immune dysfunction, with elevated IL-5 levels, that contribute to vasculitic inflammation, as confirmed on biopsy of perivascular and vascular lesions, but also to the flares observed in EGPA recurrence.23 Conversely, the pathogenic role of eosinophils in vascular inflammation is further demonstrated by the absence of vasculitis in patients receiving eosinophil-depleting therapy.24 In addition, recent studies evidenced that disease pathogenesis was not only induced by eosinophil cytolysis but also by the involvement of other immune pathways, such as IL-17 and B-cells.
Apart from systemic inflammation, positive ANCA in the sputum closely reflects pulmonary eosinophilic inflammation.25 For this reason, in EGPA with lung involvement, ANCA in sputum may emerge earlier than ANCA in blood, potentially explaining the low prevalence or absence of serum ANCA positivity. Furthermore, increased level of sputum eosinophils, together with FeNO abnormalities, suggests a more severe local inflammation due to increased pulmonary eosinophilic infiltration that can appear earlier than systemic vasculitis.
These observations suggest that, in patients with clinical and imaging characteristics, focusing on pulmonary inflammatory changes, such as ANCA and eosinophil counts in induced sputum or bronchoalveolar lavage fluid, may represent useful biomarkers to support early diagnosis in patients suspected of having EGPA but without systemic involvement.26
A recent study of 33 patients with EGPA in the vasculitic phase further evaluated biomarkers of eosinophilic activity and epithelial barrier dysfunction. Eosinophil cationic protein and specific IgE to staphylococcal enterotoxins emerged as potential markers of eosinophilic activation and barrier damage, whereas lambda free light chains showed an inverse correlation with oral corticosteroid dose, suggesting a possible role in monitoring treatment exposure and response. These preliminary findings require longitudinal validation.27
Idiopathic hypereosinophilic syndrome (HES) is a heterogeneous condition characterized by persistent hypereosinophilia and mediated end-organ damage that usually occurs without known causes.28 Commonly, signs and symptoms reflect cutaneous, pulmonary, and gastrointestinal involvement, although cardiovascular and neurologic complications can be present.
EGPA and iHES are systemic diseases characterized by hypereosinophilia, inducing organ damage that may overlap in their clinical presentations, and in the absence of clear hallmarks of vasculitis, diagnosis can be challenging.
Different authors have described these entities as two sides of the same coin, highlighting their potential clinical and pathogenic overlap.
In particular, patients with hypereosinophilia and systemic manifestations with laboratory tests negative for both myeloid and lymphocytic HES variants and for ANCA may have either HES or ANCA-negative EGPA. Currently, there are no validated disease-specific or blood-based biomarkers that allow differentiation between ANCA-negative EGPA and idiopathic HES (I-HES).8,29 However, Leurs et al demonstrated that, in patients presenting with eosinophilia and asthma, low serum levels of C-reactive protein at diagnosis may suggest HES rather than EGPA.30
This overlap is supported by the efficacy of mepolizumab in both disorders. Mepolizumab, an anti–interleukin-5 monoclonal antibody approved for severe type 2- (T2) eosinophilic asthma, is effective in both these conditions. These results suggest a shared IL-5–driven pathogenesis, supporting that T2-eosinophilic inflammation may evolve from asthma to systemic involvement.31
Indeed, EGPA tends to occur in T2-eosinophilic asthma patients as reflected in the current classification criteria (American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR)). Conversely, several trials and scientific reports have demonstrated the efficacy of mepolizumab in iHES patients presenting with asthma and lung involvement.32,33
Despite the well-documented role of eosinophils and B-cell-mediated pathways in the pathogenesis of these conditions, reliable predictive biomarkers capable of identifying progression from pulmonary type 2 eosinophilic inflammation to systemic disease remain lacking.
In fact, anti-neutrophil cytoplasmic antibodies (ANCA), associated with EGPA, can be detected in a subset of patients (approximately 30–40%), typically during the vasculitic phase. The identification of ANCA has supported the existence of two distinct pathogenetic mechanisms leading to organ damage: a T2-eosinophilic inflammatory pathway and an autoimmune, ANCA-mediated mechanism. These mechanisms predominantly operate during the asthmatic/allergic phase and the systemic vasculitic phase of the disease, respectively.34
In addition, based on the role of immunoglobulin G4 (IgG4) within the network of type 2 (T2) eosinophil-mediated inflammation, a recent study demonstrated elevated serum IgG4 levels in patients with EGPA and idiopathic HES. These findings suggest a potential role for IgG4 as a biomarker of disease progression from T2-eosinophilic asthma to EGPA and iHES.31
Primary Biliary Cholangitis: Eosinophilic Inflammation and Circulating Biomarkers
Beyond EGPA and hypereosinophilic syndromes, eosinophilic inflammation may also contribute to organ-specific autoimmune diseases. Primary biliary cholangitis represents a paradigmatic example in which eosinophils participate in tissue injury and may provide clinically relevant biomarker information.
Primary biliary cholangitis is a chronic disease of the small intrahepatic bile ducts that can lead to cirrhosis. It presents several characteristics of an autoimmune disease: specific antimitochondrial autoantibodies, association with other autoimmune diseases, prevalent female involvement and genetic component. Biliary epithelial cell damage and infiltration of the portal area are due to plasma cells, T cells, NK cells, macrophages, neutrophils, and eosinophils.35
In patients, higher frequency of eosinophils is detected both in the peripheral blood and in the liver, with a higher infiltration in the early stages of the disease, often associated with granulomas.36
Eosinophil infiltration is associated with IL-5 expression and mast cell infiltration in the liver but also with a reduction of regulatory T cells and an increased release of Th1 and Th17 cytokines. Eosinophils, infiltrated in the liver and in the ducts, release factors present in the granules such as ECP, MBP, and EDN that can also be measured in the serum and contribute to organ damage. In addition, AMA when positive may have pathologic relevance, amplifying the tissue damage as demonstrated by the serum increase of liver enzymes such as AST, ALT and ALP. Associated blood eosinophil count could be useful for monitoring liver disease over time. Approved treatment includes the use of ursodeoxycholic acid that seems to delay the progression of liver damage and reduce serum levels of liver enzymes. It was observed that patients with higher percentage of blood eosinophils at diagnosis may have a better response to the therapy with ursodeoxycholic acid.37 In patients receiving treatment, as expected, a reduction of liver enzymes is observed, but also a decrease of eosinophils. In particular, the lower frequency of eosinophils, observed both in blood and liver, seems to be due to an alteration of dendritic cells and cytokines pathway.
In some cases, eosinophilia can precede liver disease and biochemical abnormalities, highlighting a potential role for eosinophils in the early stages of primary biliary cholangitis.38
The considerable clinical and biological overlap among immune-mediated eosinophilic diseases highlights that eosinophil-driven tissue damage rarely occurs in isolation. Rather, eosinophilic inflammation is shaped and amplified by interacting immune pathways that modulate cell recruitment, activation, and effector functions. Among these, the complement system and mast cell–derived mediators emerge as critical, yet often underappreciated, regulators of eosinophilic inflammation across allergic, autoimmune, and systemic diseases.
The Role of Complement Activation and Eosinophil Pathways in Eosinophilic Diseases
As well recognized, Complement System (CS), through its activation and components, acts in host defense to enhance the ability of phagocytes and antibodies to eliminate pathogens and cellular debris.39,40 CS can also drive the pathogenesis of several diseases when dysregulated or dysfunctional.41 Therefore, both CS and eosinophils share the role of being relevant immune defense mechanisms but, when not properly functional, they can cause significant disorders. Furthermore, as the CS, eosinophils also serve as a bridge between innate and adaptive immune responses to orchestrate tissue homeostasis, repair, and remodeling.42
First, CS and eosinophils drive critical immune responses, especially during the elimination of parasites and allergic inflammation.43 The CS interacts with eosinophils primarily through specific receptors and fragments, leading to the modulation of cells’ recruitment and activation.42 Indeed, eosinophils can respond to the activated complement cascade through binding complement fragments, including anaphylatoxins (C3a and C5a), opsonins (C3b, C4b, and iC3b), and C1q, through expression of specific receptors (C3aR, C5aR, CR1, CR3, CR4, CD103 and receptors for C1q).44,45 It has been documented that several surface markers, including receptors for CS are gradually upregulated upon maturation on eosinophils and reach highest levels in mature circulating cells.46 Evidence from the literature documents that both resting and activated eosinophils express receptors for CS although their expression can be upregulated upon cell activation.46 Resting eosinophils constitutively express CR1 (CD35), CR3 (CD11b/CD18), and C3aR and C5aR while activated eosinophils can show significantly upregulated expression of these receptors (via increased density on the cell surface and/or conformational changes to functional shift) in order to increase functional activities at inflammatory and/or allergic sites. The anaphylatoxins C3a and C5a function as potent chemotactic factors that signal eosinophils to migrate to sites of inflammation and/or infection. While both eosinophils and neutrophils express the C5a receptor (C5aR or CD88), C3a acts as a chemotactic factor specifically for human eosinophils (via the C3a receptor, C3aR).47 C5aR and C3aR are both G-protein coupled receptors activating oxidative burst and calcium mobilization with subsequent production of oxygen radicals and degranulation of intracellular granules containing preformed cytokines, chemokines and growth factors, and the cationic proteins.48 Moreover, C5a is an important mediator that modulates secretion of MMP-9, a key protease for transmigration, from eosinophils and neutrophils.49,50 Since complement fragment C4a is structurally similar to C3a and C5a, it is considered an anaphylatoxin: however, an identified complement receptor for C4a has not been described as well as its specific role in direct eosinophilic chemotaxis.51 Anaphylatoxins orchestrate the inflammatory response recruiting eosinophils to infectious and/or allergic sites. Since anaphylatoxins also act on basophils and mast cells, they contribute to the release of cytokines like IL-13 and IL-4 promoting eosinophil adhesion and tissue infiltration. In this context, CS can contribute to the “eosinophil-mast cell axis,” the reciprocal interaction between these two innate immune leukocytes thereby enhancing their respective actions in Th2-mediated allergies and infections.52 Eosinophils also express receptors for opsonins (C3b and iC3b): C3b/C4b receptor (CR1/CD35) and the iC3b receptor (CR3/Mac-1/CD11b/CD18) with their opsonized targets thus mediate eosinophil adherence and activation leading to degranulation and killing of large pathogens (parasites). However, aside from eosinophil cytotoxicity and activation, CS has been shown to mediate killing of helminths.42,53 Furthermore, human eosinophils express receptors for C1q (cC1qR – calreticulin - and gC1qR) which acts as a potent chemoattractant by providing a primary signal inducing the eosinophil migration.54
CS also serves as a bridge between innate and adaptive immunity since the persistent presence of C3a and C5a may direct T cells differentiation towards a Th2 response, which further contributes to eosinophil recruitment through the production of key cytokines like IL-5. So, given these points, it is evident that CS and its fragments are bioactive mediators regulating the immune response to allergens during both the sensitization and the effector phases of allergic diseases via interactions with cells expressing their specific receptors, including eosinophils. The CS activation positively correlates with eosinophilic inflammation55. As is known, several types of disorders are commonly associated with peripheral blood or tissue eosinophilia, including allergic disorders, infectious diseases, and immune-rheumatologic diseases.56 Levels of CS components have been associated with uncontrolled asthma.57,58 Moreover, both anaphylatoxin receptors (C3aR and C5aR) were shown to have elevated expression in allergic airway diseases.59 Evidence suggests that airway allergen exposure induces a specific population of eosinophils, contrasting with resident eosinophils, expressing elevated levels of intracellular C5aR: in this view, C5a promotes the degranulation of these activated eosinophils, but does not function as an eosinophil recruitment factor.59 Several rheumatic diseases, including EGPA, eosinophilic myopathies, or eosinophilic fasciitis, are associated with CS activation and marked levels of peripheral blood or tissue eosinophilia.56,60 Moreover, in selected skin diseases, mainly autoimmune blistering diseases such as pemphigoid, C3 deposition with eosinophilic infiltrates has been described in lesional skin biopsies.61 Why and/or how the inflammatory response in these diseases induces eosinophilic versus neutrophilic infiltrations is not defined yet: certainly, the role of both C3a and C5a in activating eosinophils and thus mediating eosinophilic inflammation can be crucial. Evidence reports that the classical CS pathway (C1q) is activated in EGPA by immune complexes, which are often elevated (eg, IgG4 and IgE complexes).62 So, although EGPA is mainly a Th2-driven disease certainly characterized by hyper-eosinophilia, classical CS pathway and, thus C1q, represents a key pathogenic mechanism, along with the well documented role of alternative pathway (C5a) in AAV.63 Indeed, the necrotizing vasculitis in EGPA could be mediated by C1q-classical pathway activation through the deposition of immune complexes in small vessels and subsequent recruitment of eosinophils and neutrophils.64
Given the evidence that CS proteins directly drive eosinophil recruitment and activation and taking into account the growing interest in applications of biologics targeting eosinophils via IL-5 and IL-5Rα axis in allergic and other inflammatory diseases, it is relevant to evaluate alternative mechanisms in eosinophilic diseases by using complement-targeted therapeutics.65 Several studies document that C5 acts as a primary driver of steroid-resistant eosinophilic inflammation and support the role of anti-C5 antibodies in reducing inflammation by blocking both the recruitment and the activation of eosinophils. Furthermore, the specific complement inhibitor like eculizumab [approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG)] has been investigated in patients with allergic asthma in a safety and efficacy study (Phase II trial NCT00485576). Although evidence documented that eculizumab may be effective to attenuate allergen-induced responses, the role of anti-IL5/IL5-R in asthma remains crucial and, thus, CS-targeting therapies remain an active, albeit secondary, area of research in eosinophilic asthma.66 However, also in EGPA, the primary therapy still focuses on targeting IL-5 and thus specifically the eosinophils. Meanwhile, the approach of targeting CS-mediated damage remains secondary or can be considered in a combination therapy.62
Analyzing CS in eosinophilic diseases, although not a current primary therapeutic target, could potentially represent a useful disease biomarker, allowing for a potential stratification of disease phenotypes and/or disease activity.60,67 In the context of personalized medicine, early predictive biomarkers of disease phenotype and treatments’ efficacy might thus include CS-specific markers in order to allow for the potential use of CS-targeting therapies in highly specific subtypes of eosinophilic diseases where the CS activation acts as a primary driver.
The complex interplay between eosinophils and complement activation underscores that eosinophilic inflammation is shaped by multiple, hierarchically organized immune pathways. Translating this biological complexity into clinical decision-making requires disease models in which cytokine-driven mechanisms can be linked to measurable biomarkers and targeted therapies. Eosinophilic asthma and chronic rhinosinusitis with nasal polyps represent prototypical conditions in which such biomarker-guided, cytokine-based therapeutic strategies have been successfully implemented.
Collectively, these observations suggest that complement-related molecules may represent a complementary biomarker layer in eosinophilic diseases. Although their role in routine clinical practice remains limited, measurement of complement activation products may contribute to disease phenotyping, assessment of inflammatory activity, and identification of specific pathogenic endotypes.
Type 2 Cytokine Axes and Biomarker-Guided Biologic Therapy in Eosinophilic Asthma and CRSwNP
Eosinophilic asthma and eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) represent closely interconnected manifestations of type 2 (T2) airway inflammation, sharing common immunopathogenic mechanisms and frequently coexisting within the same patient.68 This biological and clinical overlap has reinforced the concept of a “united airway disease”, in which upper and lower airway inflammation are sustained by a coordinated cytokine network dominated by epithelial-derived alarmins and downstream T2 effector cytokines.69
At the top of the inflammatory cascade, airway epithelial cells respond to environmental insults such as allergens, respiratory viruses, and pollutants by releasing thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33.70 These epithelial alarmins activate dendritic cells, type 2 innate lymphoid cells (ILC2s), and Th2 lymphocytes, thereby amplifying T2 inflammation independently of classical IgE-mediated pathways.71 This upstream epithelial activation is increasingly recognized as a key determinant of disease severity, exacerbation risk, and corticosteroid refractoriness in both asthma and CRSwNP.72
Downstream of epithelial signaling, the canonical T2 cytokines IL-4, IL-5, and IL-13 orchestrate the effector phase of airway inflammation.7 IL-5 plays a central role in eosinophil differentiation, maturation, survival, and tissue recruitment, sustaining eosinophilic inflammation at both systemic and tissue levels.71 In parallel, IL-4 and IL-13, through signaling via the IL-4 receptor α chain, promote IgE class switching, mucus hypersecretion, epithelial barrier dysfunction, and airway hyperresponsiveness, while inducing nitric oxide synthase expression in airway epithelial cells.73 These mechanisms are highly relevant in CRSwNP, where nasal polyp tissue exhibits marked overexpression of IL-5 and IL-13, closely associated with eosinophil accumulation and remodeling processes.68
The clinical translation of this cytokine biology is reflected in the use of validated circulating and airway biomarkers to define T2 endotypes. Blood eosinophil count (BEC) represents a pragmatic surrogate of IL-5–driven systemic eosinophilic activity and has consistently been associated with increased exacerbation risk, disease severity, and responsiveness to biologic therapies targeting the IL-5 pathway.74 Fractional exhaled nitric oxide (FeNO), on the other hand, reflects IL-4/IL-13 signaling at the airway epithelial level and provides complementary information, particularly in patients with ongoing T2 inflammation despite modest eosinophil counts.74 Importantly, BEC and FeNO capture distinct but overlapping dimensions of T2 biology, and their combined assessment allows a more refined endotyping than either biomarker alone.75
The relevance of T2 biomarkers is further amplified in patients with coexisting CRSwNP. Multiple clinical trials and real-world studies have shown that the presence of nasal polyps identifies a subgroup of patients with more intense and persistent T2 inflammation and a particularly favorable response to biologic therapies.68,76,77 Anti–IL-5 and anti–IL-5 receptor α monoclonal antibodies, including mepolizumab, reslizumab, and benralizumab, exert their therapeutic effects primarily through depletion or functional inhibition of eosinophils and are especially effective in patients with elevated BEC and eosinophilic CRSwNP.68,74,78
More recently, targeting upstream epithelial cytokines has expanded the therapeutic paradigm.79 Tezepelumab, a monoclonal antibody directed against TSLP, interferes with the initiation of T2 inflammation and has demonstrated clinically meaningful efficacy across a broad spectrum of severe asthma phenotypes.70 Although the magnitude of response is greatest in patients with elevated T2 biomarkers, the ability of tezepelumab to reduce exacerbations even in patients with lower eosinophil counts underscores the pathogenic importance of epithelial alarmins in sustaining airway inflammation beyond classical eosinophilic endotypes.72
Overall, integration of cytokine biology with circulating and airway biomarkers, together with the recognition of comorbid CRSwNP, supports a precision-medicine approach to eosinophilic asthma.80 Anchoring therapeutic decisions to the dominant cytokine axis, IL-5–eosinophil, IL-4/IL-13–epithelial signaling, or upstream alarmin activation allows rational selection of biologic therapies and provides a unifying framework for managing T2-driven disease across the entire airway.80
While eosinophilic asthma and CRSwNP exemplify the successful translation of cytokine biology into biomarker-guided therapeutic strategies, this paradigm cannot be uniformly applied across all eosinophilic diseases. In particular, eosinophilic gastrointestinal diseases highlight the current limitations of circulating biomarkers and underscore the need for integrated diagnostic and monitoring approaches beyond serum-based measurements.
Among eosinophilic diseases, asthma and CRSwNP currently represent the clearest example of successful biomarker-driven precision medicine, where circulating and airway biomarkers directly inform therapeutic selection.
Eosinophilic Gastrointestinal Diseases: Current and Emerging Serum Biomarkers
Eosinophilic Gastrointestinal Diseases (EGID) comprise a heterogeneous group of rare inflammatory disorders defined by chronic gastrointestinal symptoms associated with pathological eosinophilic infiltration of the gastrointestinal mucosa, in the absence of identifiable secondary causes. Over the last five years, an international consensus effort has recommended the use of EGID as an umbrella term, with classification according to the anatomical site of involvement (eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis), in order to harmonize terminology and improve comparability across clinical and translational studies.81 Despite this conceptual advance, non-esophageal EGIDs remain poorly standardized, lacking universally accepted histological thresholds and relying largely on small observational cohorts.82,83
From a clinical standpoint, diagnosis and disease monitoring in EGID continue to depend almost exclusively on endoscopy with multiple biopsies, an invasive approach with limited feasibility for repeated follow-up, particularly in pediatric patients and in cases with multifocal gastrointestinal involvement.82,84 Recent reviews consistently identify the absence of validated non-invasive biomarkers as one of the major unmet needs in EGID, contributing to diagnostic delays and suboptimal disease monitoring.83,85 Pathogenetically, EGID are considered immune-mediated conditions frequently associated with type 2 inflammation, involving cytokines such as IL-5 and IL-13 and a central role for eosinophils as effector cells.83,86 However, recent literature emphasizes substantial biological heterogeneity across different EGID subtypes, limiting the direct translation of molecular paradigms derived from eosinophilic esophagitis to gastric or intestinal disease.86 This heterogeneity represents a critical challenge for the development of serum biomarkers capable of accurately reflecting site-specific disease activity.
Accordingly, research on serum biomarkers in EGID has primarily focused on molecules reflecting systemic eosinophil activation rather than localized mucosal inflammation. Among these, eosinophil-derived granule proteins such as eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN/EPX) have been most extensively studied.84,87 A recent systematic review on non-invasive biomarkers highlighted that while these markers are often elevated in EGID compared with controls, substantial inter-individual overlap limits their diagnostic performance when used in isolation.85
The most consistent evidence from the last five years derives from pediatric populations. A 2024 study demonstrated significantly higher serum ECP levels in children with EGID compared with healthy controls, suggesting a potential role for ECP as an adjunctive non-invasive biomarker in pediatric clinical practice.87 Nevertheless, the authors explicitly emphasized the limited specificity of ECP and the need for further prospective validation before clinical implementation.
Efforts to identify multi-marker serum signatures have also been pursued. Exploratory studies published within the last five years have assessed extended panels of cytokines, chemokines, and inflammatory proteins in EGID, starting from the assumption that no clinically validated serum biomarkers currently exist.84,85
Several cytokines involved in type 2 immunity, including IL-5, IL-13, eotaxin-3 (CCL26), and thymic stromal lymphopoietin (TSLP), have been investigated as potential circulating biomarkers. However, despite their biological relevance, available evidence remains insufficient to support their routine clinical use because serum concentrations often poorly correlate with local tissue inflammation and disease activity. Although some analytes differed statistically between patients and controls, none achieved sufficient performance for routine clinical application, reinforcing the exploratory nature of this approach.
More recently, interest has extended to treatment-associated biomarker modulation. Clinical and translational studies evaluating biologic therapies, particularly dupilumab, have reported changes in type 2 inflammatory mediators during treatment in EGID, raising the possibility that selected serum biomarkers may reflect biological response to therapy.88 However, these observations remain preliminary and have not been validated as reliable tools for disease monitoring.
Overall, evidence published in the last five years indicates that, despite a strong biological rationale, no serum biomarker is currently validated for the diagnosis or routine monitoring of EGID. Authoritative reviews converge on the view that future precision medicine approaches in EGID will require integration of serum biomarkers with clinical, histological, and multi-omics data rather than reliance on a single circulating marker.83,86 In this context, EDN and ECP should be regarded as markers of systemic eosinophilic burden useful for translational research and patient stratification, but not yet ready for routine clinical use.
Clinical Utility and Limitations of Serum Biomarkers
The clinical value of a biomarker depends on analytical reliability, association with a clinically relevant state, and the ability to change patient management. Blood eosinophil count currently has the strongest combination of accessibility and actionability, particularly in severe asthma and CRSwNP, but it is not disease-specific and varies with time, corticosteroid exposure, biologic therapy, comorbidities, and migration of eosinophils into tissues.74
Other markers answer narrower clinical questions. Baseline tryptase can support evaluation for clonal myeloid or mast-cell-associated disease, but it cannot independently establish the cause or activity of eosinophilia.15 ANCA contributes to EGPA phenotyping but has limited sensitivity and cannot exclude disease when negative.22 CRP may assist the differential diagnosis between selected ANCA-negative EGPA and HES populations,30 whereas serum IgG4 remains exploratory and has not been validated as a marker of progression.31 D-dimer should be interpreted within standard vascular diagnostic pathways because it is nonspecific for eosinophilic activity.18 Complement products remain mechanistically relevant but lack standardized assays and validated treatment-selection thresholds.55
In EGID, the principal limitation is the mismatch between circulating signals and patchy, tissue-restricted inflammation. ECP, EDN, blood eosinophils, and cytokine panels may differ between patient groups, but substantial overlap, heterogeneous assays, and incomplete correlation with histology prevent them from replacing endoscopy and biopsy.85
Across eosinophilic diseases, most candidate biomarkers have been evaluated in small, cross-sectional, or selected cohorts, with heterogeneous definitions and cut-offs and limited external validation. Serum biomarkers should therefore be interpreted longitudinally and alongside symptoms, treatment exposure, organ-specific functional testing, imaging, endoscopy, histology, and molecular investigations. Representative studies and their principal limitations are summarized in Table 1.
Table 1.
Serum Biomarkers Across Eosinophilic Diseases: Clinical Utility and Current Level of Implementation
| Disease Domain | Principal Serum Biomarkers | Main Clinical Utility | Precision Medicine Readiness |
|---|---|---|---|
| Systemic hypereosinophilia | Blood eosinophil count, serum tryptase, fibrinogen, D-dimer | Assessment of eosinophilic burden, organ involvement, and thrombotic risk | Moderate |
| EGPA and HES | Blood eosinophil count, ANCA, serum IgG4 | Disease phenotyping and monitoring | Moderate |
| Primary biliary cholangitis | Blood eosinophil count, eosinophil-derived mediators | Assessment of eosinophilic contribution to autoimmune liver disease | Low–Moderate |
| Complement-mediated eosinophilic inflammation | C3a, C5a, mast cell mediators | Endotyping and pathway characterization | Exploratory |
| Eosinophilic asthma and CRSwNP | Blood eosinophil count, FeNO, total IgE | Patient stratification and biologic selection | High |
| EGID | Eosinophil granule proteins, IL-5, IL-13, CCL26, TSLP | Exploratory assessment of disease activity and potential treatment monitoring | Exploratory |
Notes: This table summarizes the principal circulating biomarkers currently investigated or used across eosinophilic diseases, their main clinical applications, and their degree of implementation within precision medicine strategies. While eosinophilic asthma and chronic rhinosinusitis with nasal polyps currently represent the most mature examples of biomarker-guided therapeutic decision-making, several systemic and gastrointestinal eosinophilic disorders still rely on exploratory biomarkers requiring further clinical validation.
Conclusions: Toward Precision Medicine in Eosinophilic Diseases
Eosinophilic diseases represent a biologically interconnected spectrum rather than a collection of isolated organ-specific conditions. Across allergic, inflammatory, autoimmune, and hematologic disorders, eosinophilia reflects shared immune pathways that can manifest with highly variable clinical phenotypes, ranging from localized tissue inflammation to multisystem involvement with cardiovascular, renal, hepatic, and thrombotic complications. Recognizing this systemic dimension is essential for advancing precision medicine in eosinophilic disorders.
Circulating biomarkers provide critical insights into the pathogenic mechanisms underlying eosinophilic diseases. Peripheral blood eosinophil count remains a cornerstone marker of disease activity and therapeutic response, particularly in conditions driven by interleukin-5–dependent eosinophilic inflammation. However, eosinophil count alone is insufficient to capture the complexity of eosinophilic disorders. Markers of coagulation activation, mast cell–derived mediators such as tryptase, complement components, and type 2 inflammatory biomarkers reflect additional, clinically relevant axes of disease biology, including vascular injury, immune amplification, and thrombotic risk.
The clinical impact of biomarker integration is most clearly illustrated in eosinophilic asthma and chronic rhinosinusitis with nasal polyps, where cytokine-driven endotyping has enabled rational selection of biologic therapies and improved patient outcomes. In contrast, in systemic eosinophilic syndromes, immune-mediated diseases, and eosinophilic gastrointestinal disorders, serum biomarkers remain largely exploratory and must be interpreted in conjunction with clinical, imaging, endoscopic, and histological data. These conditions highlight the current limitations of relying on single biomarkers and underscore the need for multidimensional approaches.
From a clinical perspective, a stepwise approach is warranted: first, define the eosinophilic phenotype and exclude secondary or clonal causes; second, combine serum biomarkers with targeted assessment of organs at risk; and third, use a biomarker to guide treatment only in settings in which clinical actionability has been demonstrated, as in severe eosinophilic asthma and CRSwNP. Outside these settings, biomarkers should remain adjunctive rather than stand-alone diagnostic or therapeutic tools.
Future studies should prioritize prospective multicenter validation, standardized assays and sampling conditions, prespecified thresholds, and direct comparison with existing clinical assessment. Composite panels will be clinically meaningful only if they improve diagnosis, risk prediction, or treatment selection beyond simpler and more accessible measures.
Overall, achieving precision medicine in eosinophilic diseases requires a shift from organ-centered frameworks toward integrated biomarker-driven strategies that reflect the underlying immune biology. Future research should focus on validating composite biomarker panels, clarifying their prognostic and predictive value, and integrating serum biomarkers with tissue-based and multi-omics data. Such efforts are essential to translate mechanistic insights into individualized, effective management strategies across the full spectrum of eosinophilic diseases.
Importantly, the level of biomarker maturity varies substantially across eosinophilic diseases. While airway diseases currently provide the most successful example of biomarker-guided precision medicine, several systemic and gastrointestinal eosinophilic disorders still lack validated biomarkers capable of guiding diagnosis, prognosis, and therapeutic decisions. Bridging this gap represents one of the major challenges for future research.
Funding Statement
The authors declare that no funding was received for this work.
Abbreviations
ANCA, antineutrophil cytoplasmic antibodies; CCL, C-C motif chemokine ligand; CCR3, C-C chemokine receptor type 3; CRP, C-reactive protein; CRSwNP, chronic rhinosinusitis with nasal polyps; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EGID, eosinophilic gastrointestinal diseases; EGPA, eosinophilic granulomatosis with polyangiitis; EPO, eosinophil peroxidase; HES, hypereosinophilic syndrome; IgG4, immunoglobulin G4; ILC2, type 2 innate lymphoid cells; MBP, major basic protein; ROS, reactive oxygen species; TSLP, thymic stromal lymphopoietin.
Data Sharing Statement
Data sharing is not applicable to this article as no data were created or analysed in this study.
Author Contributions
Mona-Rita Yacoub and Remo Poto share first authorship. C. Caruso: Conceptualization, Investigation, Validation, Visualization, Writing – Original Draft, Writing – Review & Editing, Supervision. M.R. Yacoub: Conceptualization, Resources, Supervision, Writing – Original Draft. C. Milito: Conceptualization, Supervision, Writing – Original Draft. P. Triggianese: Investigation, Visualization, Writing – Original Draft. R. Poto: Conceptualization, Investigation, Validation, Visualization, Supervision, Writing – Original Draft, Writing – Review & Editing. L. Bruno: Supervision, Validation, Methodology, Formal analysis, Data curation, Conceptualization, Writing – Original Draft, Writing – Review & Editing. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
The authors declare that they have no competing interests.
References
- 1.Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7(2):e1393134. PubMed PMID: 29308325. doi: 10.1080/2162402X.2017.1393134 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gao YD, Wang ZJ, Ogulur I, et al. The evolution, immunopathogenesis and biomarkers of type 2 inflammation in common allergic disorders. Allergy. 2025;80(7):1848–18. PubMed PMID: 40586319. doi: 10.1111/all.16620 [DOI] [PubMed] [Google Scholar]
- 3.Gigon L, Fettrelet T, Yousefi S, Simon D, Simon HU. Eosinophils from A to Z. Allergy. 2023;78(7):1810–1846. PubMed PMID: 37102676. doi: 10.1111/all.15751 [DOI] [PubMed] [Google Scholar]
- 4.Mattei F, Andreone S, Marone G, et al. Eosinophils in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:1–28. PubMed PMID: 33119873. doi: 10.1007/978-3-030-49270-0_1 [DOI] [PubMed] [Google Scholar]
- 5.Macchia I, La Sorsa V, Urbani F, et al. Eosinophils as potential biomarkers in respiratory viral infections. Front Immunol. 2023;14:1170035. PubMed PMID: 37483591. doi: 10.3389/fimmu.2023.1170035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Portacci A, Poto R, Varricchi G, Carpagnano GE. Dupilumab and blood eosinophilia: a disease-specific phenomenon? Allergy. 2025;80(6):1811–1814. PubMed PMID: 40492692. doi: 10.1111/all.16610 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Poto R, Portacci A, Chan R, Lagnese G, Giovannini M, Varricchi G. Advancing precision medicine for asthma by focusing on type 2 cytokines and alarmins. Curr Opin Allergy Clin Immunol. 2025;25(4):269–276. PubMed PMID: 40464795. doi: 10.1097/ACI.0000000000001081 [DOI] [PubMed] [Google Scholar]
- 8.Khoury P, Zagallo P, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy. 2012;67(9):1149–1156. PubMed PMID: 22775568. doi: 10.1111/j.1398-9995.2012.02873.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gao SJ, Wei W, Chen JT, et al. Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: a case report and literature review. Medicine. 2016;95(35):e4658. PubMed PMID: 27583887. doi: 10.1097/MD.0000000000004658 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Marzano AV, Tedeschi A, Rossio R, Fanoni D, Cugno M. Prothrombotic state in Churg-Strauss syndrome: a case report. J Investig Allergol Clin Immunol. 2010;20(7):616–619. PubMed PMID: 21314005. [PubMed] [Google Scholar]
- 11.Collini V, Burelli M, Favaretto V, et al. Eosinophilic myocarditis: comprehensive update on pathophysiology, diagnosis, prognosis and management. Minerva Cardiol Angiol. 2023;71(5):535–552. PubMed PMID: 37161920. doi: 10.23736/S2724-5683.23.06287-7 [DOI] [PubMed] [Google Scholar]
- 12.Ferreira J, Gonçalves S, Duarte T, Quintal J, Coelho R, Costa C. The three stages of eosinophilic cardiac damage: a series of case reports. J Cardiol Cases. 2024;30(1):5–8. PubMed PMID: 39007045. doi: 10.1016/j.jccase.2024.02.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sharma S, Desai S, Leoni J, Paghdar S, Ruiz J, Goswami R. Case report: eosinophilic myocarditis in hypereosinophilic syndrome: a journey to heart transplantation. Front Immunol. 2024;15:1418665. PubMed PMID: 38911849. doi: 10.3389/fimmu.2024.1418665 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Asada AM, Kahwash R, Trovato V. Eosinophilic myocarditis: a concise review. Curr Cardiol Rep. 2025;27(1):38. PubMed PMID: 39847306. doi: 10.1007/s11886-024-02184-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Tefferi A, Pardanani A, Li CY. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? Blood. 2003;102(8):3073–4; author reply 3074. PubMed PMID: 14527892. doi: 10.1182/blood-2003-07-2274 [DOI] [PubMed] [Google Scholar]
- 16.Ramirez GA, Ripa M, Burastero S, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses. Microorganisms. 2023;11(2):346. PubMed PMID: 36838310. doi: 10.3390/microorganisms11020346 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wang H, Zhong H, Chen W, Cheng H, Hao F, Song Z. Idiopathic hypereosinophilic syndrome with cutaneous necrosis and multiorgan embolism. JAAD Case Rep. 2019;5(12):1041–1044. PubMed PMID: 31763430. doi: 10.1016/j.jdcr.2019.07.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Song Y, Yang B, Ren W, Hu D. Elevation of D-dimer in eosinophilic gastrointestinal diseases in the absence of venous thrombosis: a case series and literature review. Open Med. 2024;19(1):20240960. PubMed PMID: 38756250. doi: 10.1515/med-2024-0960 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Png CYM, Nakazawa KR, Lau IH, Tadros RO, Faries PL, Ting W. Bilateral May-Thurner syndrome refractory to iliac aneurysm repair. J Vasc Surg Venous Lymphat Disord. 2018;6(5):657–660. PubMed PMID: 29945821. doi: 10.1016/j.jvsv.2018.03.014 [DOI] [PubMed] [Google Scholar]
- 20.Pallotti F, Mettler C, Papo M, et al. Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: insights from a European multicenter study. J Intern Med. 2026;299:(3): 349–364. doi: 10.1111/joim.70056 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120. doi: 10.1038/s41467-019-12515-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Chang HC, Chou PC, Lai CY, Tsai HH. Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021;9(1):445–452.e6. doi: 10.1016/j.jaip.2020.07.038 [DOI] [PubMed] [Google Scholar]
- 23.Lu C, Ou C, Deng Y, et al. Clinical, biomarker, and radiological progression from asthma to systemic eosinophilic granulomatosis with polyangiitis: a retrospective cohort study. J Asthma Allergy. 2025;18:1615–1626. doi: 10.2147/JAA.S542255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Magrone T, Magrone M, Jirillo E. Eosinophils, a jack of all trades in immunity: therapeutic approaches for correcting their functional disorders. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1166–1181. doi: 10.2174/1871530320666200309094726 [DOI] [PubMed] [Google Scholar]
- 25.Zwerina J, Strehl JD, Beyer C, Schett G. Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome? Clin Exp Rheumatol. 2013;31(6):989–990. PubMed PMID: 24144017. [PubMed] [Google Scholar]
- 26.Latorre M, Seccia V, Puxeddu I, et al. Severe Eosinophilic asthma or eosinophilic granulomatosis with polyangiitis: potential biomarkers for novel diagnostic strategies. J Allergy Clin Immunol Pract. 2024;12(11):3057–3067. doi: 10.1016/j.jaip.2024.08.011 [DOI] [PubMed] [Google Scholar]
- 27.Caruso C, Baglivo I, Colantuono S, et al. Immunological and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers. Explor Asthma Allergy. 2026;4:1009127. doi: 10.37349/eaa.2026.1009127 [DOI] [Google Scholar]
- 28.Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612.e9. doi: 10.1016/j.jaci.2012.02.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pagnoux C, Nair P, Xi Y, et al. Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clin Exp Rheumatol. 2019;37(Suppl 117):40–44. PubMed PMID: 30652675. [PMC free article] [PubMed] [Google Scholar]
- 30.Leurs A, Chenivesse C, Lopez B, et al. C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody–negative eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2019;7(4):1347–1351.e3. doi: 10.1016/j.jaip.2018.10.002 [DOI] [PubMed] [Google Scholar]
- 31.Piga MA, Martini M, Fraticelli P, et al. Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome. Clin Exp Rheumatol. 2025;43(4):710–717. doi: 10.55563/clinexprheumatol/3ihc3t [DOI] [PubMed] [Google Scholar]
- 32.Kuang FL, Fay MP, Ware J, et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J Allergy Clin Immunol Pract. 2018;6(5):1518–1527.e5. doi: 10.1016/j.jaip.2018.04.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397–1405. doi: 10.1016/j.jaci.2020.08.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med. 2021;8. doi: 10.3389/fmed.2021.627776 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Diny NL, Rose NR, Čiháková D. Eosinophils in autoimmune diseases. Front Immunol. 2017;8. doi: 10.3389/fimmu.2017.00484 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Liang Y, Khandakar B, Hao Y, Xiong Y, Liu BL, Zhang X. Histology and clinical correlations in autoimmune hepatitis, primary biliary cholangitis, and autoimmune hepatitis-primary biliary cholangitis overlap syndrome. Ann Diagn Pathol. 2023;67:152178. doi: 10.1016/j.anndiagpath.2023.152178 [DOI] [PubMed] [Google Scholar]
- 37.Willart MAM, van Nimwegen M, Grefhorst A, et al. Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy. 2012;67(12):1501–1510. doi: 10.1111/all.12019 [DOI] [PubMed] [Google Scholar]
- 38.Long H, Zhang G, Wang L, Lu Q. Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):189–213. doi: 10.1007/s12016-015-8485-8 [DOI] [PubMed] [Google Scholar]
- 39.Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. 2024;24(2):118–141. doi: 10.1038/s41577-023-00926-1 [DOI] [PubMed] [Google Scholar]
- 40.Conigliaro P, Triggianese P, Ballanti E, Perricone C, Perricone R, Chimenti MS. Complement, infection, and autoimmunity. Curr Opin Rheumatol. 2019;31(5):532–541. PubMed PMID: 31192812. doi: 10.1097/BOR.0000000000000633 [DOI] [PubMed] [Google Scholar]
- 41.West EE, Woodruff T, Fremeaux-Bacchi V, Kemper C. Complement in human disease: approved and up-and-coming therapeutics. Lancet. 2024;403(10424):392–405. PubMed PMID: 37979593. doi: 10.1016/S0140-6736(23)01524-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Shamri R, Xenakis JJ, Spencer LA. Eosinophils in innate immunity: an evolving story. Cell Tissue Res. 2011;343(1):57–83. PubMed PMID: 21042920. doi: 10.1007/s00441-010-1049-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113(1):30–37. PubMed PMID: 14713904. doi: 10.1016/j.jaci.2003.10.050 [DOI] [PubMed] [Google Scholar]
- 44.Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev. 1999;51(2):213–340. PubMed PMID: 10353986. [PubMed] [Google Scholar]
- 45.Walsh GM, Hartnell A, Moqbel R, et al. Receptor expression and functional status of cultured human eosinophils derived from umbilical cord blood mononuclear cells. Blood. 1990;76(1):105–111. PubMed PMID: 1973060. doi: 10.1182/blood.V76.1.105.105 [DOI] [PubMed] [Google Scholar]
- 46.Hassani M, van Staveren S, van Grinsven E, et al. Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals. Haematologica. 2020;105(2):e52–6. PubMed PMID: 31101758. doi: 10.3324/haematol.2019.219048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709–750. PubMed PMID: 18384431. doi: 10.1111/j.1365-2222.2008.02958.x [DOI] [PubMed] [Google Scholar]
- 48.DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int Immunopharmacol. 2007;7(14):1909–1923. PubMed PMID: 18039528. doi: 10.1016/j.intimp.2007.07.006 [DOI] [PubMed] [Google Scholar]
- 49.DiScipio RG, Schraufstatter IU, Sikora L, Zuraw BL, Sriramarao P. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int Immunopharmacol. 2006;6(7):1109–1118. PubMed PMID: 16714214. doi: 10.1016/j.intimp.2006.02.006 [DOI] [PubMed] [Google Scholar]
- 50.Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med. 1995;181(6):2119–2127. PubMed PMID: 7760001. doi: 10.1084/jem.181.6.2119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Wang H, Ricklin D, Lambris JD. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci U S A. 2017;114(41):10948–10953. PubMed PMID: 28973891. doi: 10.1073/pnas.1707364114 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Wong CK, Ng SSM, Lun SWM, Cao J, Lam CWK. Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology. 2009;126(4):579–587. PubMed PMID: 18771439. doi: 10.1111/j.1365-2567.2008.02916.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Ramalho-Pinto FJ, McLaren DJ, Smithers SR. Complement-mediated killing of schistosomula of Schistosoma mansoni by rat eosinophils in vitro. J Exp Med. 1978;147(1):147–156. PubMed PMID: 627834. doi: 10.1084/jem.147.1.147 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Kuna P, Iyer M, Peerschke EI, Kaplan AP, Reid KB, Ghebrehiwet B. Human C1q induces eosinophil migration. Clin Immunol Immunopathol. 1996;81(1):48–54. PubMed PMID: 8808641. doi: 10.1006/clin.1996.0156 [DOI] [PubMed] [Google Scholar]
- 55.Dong C, Lu S, Deng Z, et al. Role for complement C5 in Eosinophilic inflammation of severe asthma. Allergy. 2026;81:(5): 1571–1586. PubMed PMID: 40524528. doi: 10.1111/all.16616 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Tamaki H, Chatterjee S, Langford CA. Eosinophilia in rheumatologic/vascular disorders. Immunol Allergy Clin North Am. 2015;35(3):453–476. PubMed PMID: 26209895. doi: 10.1016/j.iac.2015.05.001 [DOI] [PubMed] [Google Scholar]
- 57.Weiszhár Z, Bikov A, Gálffy G, et al. Elevated complement factor H levels in asthmatic sputa. J Clin Immunol. 2013;33(2):496–505. PubMed PMID: 23070659. doi: 10.1007/s10875-012-9807-8 [DOI] [PubMed] [Google Scholar]
- 58.Du F, Wang H, Chen Z, et al. Induced sputum transcriptomics profile and serum c3 are associated with asthma severity. J Asthma Allergy. 2025;18:1051–1064. PubMed PMID: 40584937. doi: 10.2147/JAA.S517140 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Thomas SA, Lajoie S. Complement’s involvement in allergic Th2 immunity: a cross-barrier perspective. J Clin Invest. 2025;135(9). PubMed PMID: 40309766. doi: 10.1172/JCI188352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Triggianese P, Conigliaro P, De Martino E, Monosi B, Chimenti MS. Overview on the link between the complement system and auto-immune articular and pulmonary disease. Open Access Rheumatol. 2023;15:65–79. PubMed PMID: 37214353. doi: 10.2147/OARRR.S318826 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Zeng FAP, Murrell DF. Bullous pemphigoid-what do we know about the most recent therapies? Front Med. 2022;9:1057096. PubMed PMID: 36405625. doi: 10.3389/fmed.2022.1057096 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Emmi G, Bettiol A, Gelain E, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378–393. PubMed PMID: 37161084. doi: 10.1038/s41584-023-00958-w [DOI] [PubMed] [Google Scholar]
- 63.Rolla G, Guida G, Heffler E. Churg-Strauss syndrome: still a clinical challenge. Expert Rev Clin Immunol. 2007;3(6):833–837. PubMed PMID: 20477130. doi: 10.1586/1744666X.3.6.833 [DOI] [PubMed] [Google Scholar]
- 64.Yap BJM, Lai-Foenander AS, Goh BH, et al. Unraveling the immunopathogenesis and genetic variants in vasculitis toward development of personalized medicine. Front Cardiovasc Med. 2021;8:732369. PubMed PMID: 34621800. doi: 10.3389/fcvm.2021.732369 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Ricklin D. Complement-targeted therapeutics: are we there yet, or just getting started? Eur J Immunol. 2024;54(12). doi: 10.1002/eji.202350816 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Smith SG, Watson B, Clark G, Gauvreau GM. Eculizumab for treatment of asthma. Expert Opin Biol Ther. 2012;12(4):529–537. PubMed PMID: 22413827. doi: 10.1517/14712598.2012.668517 [DOI] [PubMed] [Google Scholar]
- 67.Kawakami T, Kimura S, Takeuchi S, Soma Y. Relationship among antineutrophil cytoplasmic antibody, blood urea nitrogen and complement in patients with eosinophilic granulomatosis polyangiitis (Churg-Strauss syndrome). J Dermatol. 2013;40(7):511–515. PubMed PMID: 23594281. doi: 10.1111/1346-8138.12163 [DOI] [PubMed] [Google Scholar]
- 68.Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551. PubMed PMID: 29731100. doi: 10.1016/j.jaci.2018.03.004 [DOI] [PubMed] [Google Scholar]
- 69.Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. PubMed PMID: 25521684. doi: 10.1038/ni.3049 [DOI] [PubMed] [Google Scholar]
- 70.Pelaia C, Melhorn J, Paoletti G, et al. Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma. Front Allergy. 2025;6:1671353. PubMed PMID: 41321706. doi: 10.3389/falgy.2025.1671353 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Varricchi G, Poto R. Towards precision medicine in COPD: targeting type 2 cytokines and alarmins. Eur J Intern Med. 2024;125:28–31. PubMed PMID: 38762432. doi: 10.1016/j.ejim.2024.05.011 [DOI] [PubMed] [Google Scholar]
- 72.Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. PubMed PMID: 33979488. doi: 10.1056/NEJMoa2034975 [DOI] [PubMed] [Google Scholar]
- 73.Sahnoon L, Bajbouj K, Mahboub B, Hamoudi R, Hamid Q. Targeting IL-13 and IL-4 in asthma: therapeutic implications on airway remodeling in severe asthma. Clin Rev Allergy Immunol. 2025;68(1):44. PubMed PMID: 40257546. doi: 10.1007/s12016-025-09045-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. PubMed PMID: 27609408. doi: 10.1016/S0140-6736(16)31324-1 [DOI] [PubMed] [Google Scholar]
- 75.Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024;12(4):809–823. PubMed PMID: 38280454. doi: 10.1016/j.jaip.2024.01.023 [DOI] [PubMed] [Google Scholar]
- 76.Hopkins C. Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55–63. PubMed PMID: 31269366. doi: 10.1056/NEJMcp1800215 [DOI] [PubMed] [Google Scholar]
- 77.Detoraki A, Tremante E, D’Amato M, et al. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis. 2021;15:17534666211009398. PubMed PMID: 33910399. doi: 10.1177/17534666211009398 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. PubMed PMID: 25736990. doi: 10.1016/S2213-2600(15)00042-9 [DOI] [PubMed] [Google Scholar]
- 79.Varricchi G, Poto R, Lommatzsch M, et al. Biologics and airway remodeling in asthma: early, late, and potential preventive effects. Allergy. 2025;80(2):408–422. PubMed PMID: 39520155. doi: 10.1111/all.16382 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. PubMed PMID: 28911920. doi: 10.1016/S0140-6736(17)30879-6 [DOI] [PubMed] [Google Scholar]
- 81.Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474–2484.e3. PubMed PMID: 35181570. doi: 10.1016/j.cgh.2022.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Lucendo AJ, Molina-Infante J. Eosinophilic oesophagitis: current evidence-based diagnosis and treatment. Gastroenterol Hepatol. 2018;41(4):281–291. PubMed PMID: 29422238. doi: 10.1016/j.gastrohep.2017.12.007 [DOI] [PubMed] [Google Scholar]
- 83.Kinoshita Y, Oouchi S, Fujisawa T. Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. Allergol Int. 2019;68(4):420–429. PubMed PMID: 31000445. doi: 10.1016/j.alit.2019.03.003 [DOI] [PubMed] [Google Scholar]
- 84.Papaiakovou G, Papageorgiou A, Bakakos A, Sinaniotis AC, Rovina N. Eosinophilic gastrointestinal diseases: current perspectives on pathogenesis and management. Explor Asthma Allergy. 2024;2:205–218. doi: 10.37349/eaa.2024.00041 [DOI] [Google Scholar]
- 85.Noble SL, Tyrrell R, Mules TC, Inns S. Non-invasive biomarkers to diagnose and monitor eosinophilic esophagitis: a systematic review. Front Med. 2025;12:1607306. PubMed PMID: 40641963. doi: 10.3389/fmed.2025.1607306 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Redd WD, Dellon ES. Eosinophilic gastrointestinal diseases beyond the esophagus: an evolving field and nomenclature. Gastroenterol Hepatol. 2022;18(9):522–528. PubMed PMID: 36397988. [PMC free article] [PubMed] [Google Scholar]
- 87.Kim HR, Kim Y, Moon JS, Ko JS, Yang HR. Serum Eosinophilic cationic protein as a useful noninvasive marker of eosinophilic gastrointestinal disease in children. Pediatr Gastroenterol Hepatol Nutr. 2024;27(2):79–87. PubMed PMID: 38510583. doi: 10.5223/pghn.2024.27.2.79 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Sia T, Bacchus L, Tanaka R, Khuda R, Mallik S, Leung J. Dupilumab can induce remission of Eosinophilic gastritis and duodenitis: a retrospective case series. Clin Transl Gastroenterol. 2024;15(1):e00646. PubMed PMID: 37753954. doi: 10.14309/ctg.0000000000000646 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no data were created or analysed in this study.
